Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

PURPOSE: We conducted a phase II randomized noncomparative window of opportunity (WOO) trial to evaluate the inhibition of cellular proliferation and the modulation of immune microenvironment after treatment with olaparib alone or in combination with cisplatin or durvalumab in patients with operable...

Descripción completa

Detalles Bibliográficos
Autores principales: Moutafi, Myrto, Koliou, Georgia-Angeliki, Papaxoinis, George, Economopoulou, Panagiota, Kotsantis, Ioannis, Gkotzamanidou, Maria, Anastasiou, Maria, Pectasides, Dimitrios, Kyrodimos, Efthymios, Delides, Alexander, Giotakis, Evangelos, Papadimitriou, Nikolaos G., Panayiotides, Ioannis G., Perisanidis, Christos, Fernandez, Aileen I., Xirou, Vasiliki, Poulios, Christos, Gagari, Eleni, Yaghoobi, Vesal, Gavrielatou, Niki, Shafi, Saba, Aung, Thazin Nwe, Kougioumtzopoulou, Andromachi, Kouloulias, Vassilis, Palialexis, Konstantinos, Gkolfinopoulos, Stavros, Strati, Areti, Lianidou, Evi, Fountzilas, George, Rimm, David L., Foukas, Periklis G., Psyrri, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414130/
https://www.ncbi.nlm.nih.gov/pubmed/37575280
http://dx.doi.org/10.1158/2767-9764.CRC-23-0051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414130/
https://www.ncbi.nlm.nih.gov/pubmed/37575280
http://dx.doi.org/10.1158/2767-9764.CRC-23-0051

Ejemplares similares